Helocyte is a biopharmaceutical company developing immunotherapies for the prevention and treatment of cancer and infectious diseases. It is engaged in the development of Triplex, a recombinant viral vector vaccine designed to induce a durable virus-specific T cell response to control cytomegalovirus (CMV) in transplant recipients.